226. Ghosh R, Liddle BJ. Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome. Postgrad Med J. 2011 Feb;87(1024):125-31. doi: 10.1136/pgmj.2010.104976. Epub 2010 Nov 24. PMID: 21106801.
227. Prasad S, Pal PK. When time is of the essence: Managing care in emergency situations in Parkinson's disease. Parkinsonism Relat Disord. 2019 Feb;59:49-56. doi: 10.1016/j.parkreldis.2018.09.016. Epub 2018 Sep 18. PMID: 30253924.
228. Kaasinen V, Joutsa J, Noponen T, Päivärinta M. Akinetic crisis in Parkinson's disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases. Case Rep Neurol. 2014 Nov 26;6(3):275-80. doi: 10.1159/000369448. PMID: 25566059; PMCID: PMC4280458.
229. Bächli E, Albani C. Die akinetische Krise beim Morbus Parkinson [Akinetic crisis in Parkinson disease]. Schweiz Med Wochenschr. 1994 Jun 11;124(23):1017-23. German. PMID: 8023100.
230. Wang M, Wang W, Gao Z, Yin X, Chen T, Jiang Z, Wang Z. Dyskinesia- hyperpyrexia syndrome in Parkinson's disease: a systematic review. Clin Auton Res. 2021 Apr 7. doi: 10.1007/s10286-021-00801-w. Epub ahead of print. PMID: 33826041.
231. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson's disease. Intern Med J. 2006 Aug;36(8):524-6. doi: 10.1111/j.1445-5994.2006.01123.x. PMID: 16866658.
232. Chan DK, Cordato DJ, O'Rourke F. Management for motor and non-motor complications in late Parkinson's disease. Geriatrics. 2008 May;63(5):22-7. PMID: 18447408.
233. Ebersbach G, Ip CW, Klebe S, Koschel J, Lorenzl S, Schrader C, Winkler C, Franke C. Management of delirium in Parkinson's disease. J Neural Transm (Vienna). 2019 Jul;126(7):905-912. doi: 10.1007/s00702-019-01980-7. Epub 2019 Feb 6. PMID: 30725186.
234. Dag Aarsland, MD, PhD; Robert Perry, FrCPath; Jan P. Larsen, MD, PhD; Ian G. McKeith, FRCPysch; John T. O'Brien, MRCPsych; Elaine K. Perry, PhD; David Burn, MD; and Clive G. Ballard, MRCPsych, MD. Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. J Clin Psychiatry 2005;66(5):633-637
235. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018 Jan 4;20(1):17r02185. doi: 10.4088/PCC.17r02185. PMID: 29325237.
236. Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019 Jun 20;10:2042098619854007. doi: 10.1177/2042098619854007. PMID: 31258887; PMCID: PMC6587390.
237. de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 Jan;70:55-59. doi: 10.1016/j.parkreldis.2019.12.011. Epub 2019 Dec 17. PMID: 31865063.
238. Jeong S, Cho H, Kim YJ, Ma HI, Jang S. Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease. PLoS One. 2021 Mar 1;16(3):e0247354. doi: 10.1371/journal.pone.0247354. PMID: 33647030; PMCID: PMC7920346.
239. Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect. 1993;6(1):63-72. doi: 10.1007/BF02252624. PMID: 8105799.
240. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018 Jan 4;20(1):17r02185. doi: 10.4088/PCC.17r02185. PMID: 29325237.
241. Onofrj M. et al. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment //Parkinsonism & related disorders. – 2009. – Т. 15. C. S233-S236.
242. Lee JY, Oh S, Kim JM, Kim JS, Oh E, Kim HT, Jeon BS, Cho JW. Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial. J Neurol. 2013 Dec;260(12):3030-8. doi: 10.1007/s00415-013-7108-7. Epub 2013 Sep 22. PMID: 24057149.
243. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 1975 Jul;25(7):603-6. doi: 10.1212/wnl.25.7.603. PMID: 807867.
244. Wang M, Wang W, Gao Z, Yin X, Chen T, Jiang Z, Wang Z. Dyskinesia- hyperpyrexia syndrome in Parkinson's disease: a systematic review. Clin Auton Res. 2021 Apr 7. doi: 10.1007/s10286-021-00801-w. Epub ahead of print. PMID: 33826041.
245. Baek MS, Lee HW, Lyoo CH, Seok Baek M, Woo Lee H, Hyoung Lyoo C. A patient with recurrent dyskinesia and hyperpyrexia syndrome. JMD 2017;10:154–7.
246. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003467. doi: 10.1002/14651858.CD003467. PMID: 12804468.
247. Kong M, Ba M, Ren C, Yu L, Dong S, Yu G, Liang H. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. Oncotarget. 2017 May 5;8(34):57316-57326. doi: 10.18632/oncotarget.17622. PMID: 28915672; PMCID: PMC5593643.
248. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T; Amantadine Study Group. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One. 2010 Dec 31;5(12):e15298. doi: 10.1371/journal.pone.0015298. PMID: 21217832; PMCID: PMC3013111.
249. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double- blind placebo-controlled study. Mov Disord. 2001 May;16(3):515-20. doi: 10.1002/mds.1112. PMID: 11391748.
250. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999 Nov;56(11):1383-6. doi: 10.1001/archneur.56.11.1383. PMID: 10555659.
251. Widman LP, Burke WJ, Pfeiffer RF, McArthur-Campbell D. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. J Geriatr Psychiatry Neurol. 1997 Apr;10(2):63-6. doi: 10.1177/089198879701000205. PMID: 9188021.